Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTAM study of probenecid boosting endoxifen exposure during tamoxifen treatment
NL-OMON49150Phase 4Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tamoxifen and probenecid in breast cancer, sponsored by Erasmus MC. Primary endpoint: Endoxifen area under the curve. Started May 2020; status: active, not recruiting.
02
Drugs
tamoxifenprobenecid
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON49150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49150.